Literature DB >> 12908017

The maternal benefits of corticosteroids with HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome.

Joan M G Crane1, Baharak Tabarsi, Donna Hutchens.   

Abstract

OBJECTIVES: To determine the more effective regime in improving hematologic abnormalities associated with HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome, by comparing two different antenatal dosing protocols for dexamethasone (given primarily for fetal lung maturity). STUDY
DESIGN: A retrospective cohort study of 30 women between 24 and 34 weeks' gestation, diagnosed with HELLP syndrome prior to delivery, who received 2 doses of dexa-methasone 12 mg intramuscularly, given either 24 hours apart or 12 hours apart.
RESULTS: There was a shorter time from the first corticosteroid dose to the beginning of improvement with the 12-hour regime for platelet count (11 hours [9, 25 hours] versus 69 hours [41, 112 hours], median [quartiles], P = 0.003) and for alkaline phosphatase (25 hours [5, 44 hours] versus 59 hours [31, 69 hours], median [quartiles], P = 0.02). Worsening recurred from 11 hours, for alanine aminotransferase (ALT) and aspartate transaminase (AST), to 32 hours, for uric acid, after initial improvement. Hematologic improvement occurred in 37% (for ALT) to 67% (for alkaline phosphatase) of women overall.
CONCLUSION: A temporary improvement in the hematologic parameters of HELLP syndrome can occur with antenatal dexa-methasone administration, with the 12-hour regime having quicker onset to improvement in platelet count and alkaline phosphatase.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12908017     DOI: 10.1016/s1701-2163(16)30123-2

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  3 in total

Review 1.  Corticosteroids for HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome.

Authors:  Timothy L Clenney; Anthony J Viera
Journal:  BMJ       Date:  2004-07-31

2.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

Review 3.  Corticosteroid Therapy for Management of Hemolysis, Elevated Liver Enzymes, and Low Platelet Count (HELLP) Syndrome: A Meta-Analysis.

Authors:  Minhong Mao; Chen Chen
Journal:  Med Sci Monit       Date:  2015-12-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.